Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
Kevin J HarringtonAnthony KongNicolas MachJason A ChesneyBeatriz Castelo FernandezDanny RischinEzra E W CohenHoi-Shen RadcliffeBurak GumuscuJonathan ChengWendy SnyderLillian L SiuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The combination of T-VEC and pembrolizumab demonstrated a tolerable safety profile in R/M HNSCC. The efficacy with the combination was similar to that with pembrolizumab monotherapy in historical HNSCC studies. Phase III part of this study was not further pursued (ClinicalTrials.gov Identifier: NCT02626000).